Adalimumab-Induced Lupus Serositis: A Case Report and Review of the Literature.
Cureus
; 15(2): e34568, 2023 Feb.
Article
en En
| MEDLINE
| ID: mdl-36874325
ABSTRACT
Tumor necrosis factor-alpha (TNF-alpha) antagonist use is prevalent for the treatment of autoimmune diseases, including psoriasis, ankylosing spondylitis, and rheumatoid arthritis. Since the onset of its use over the last couple of decades, there have been increasing reports of drug-induced antibodies and antitumor necrosis factor-alpha-induced lupus (ATIL). Herein, we present a case of pericarditis induced by tumor necrosis factor-alpha antagonist, adalimumab. A 61-year-old male with psoriatic arthritis treated with adalimumab injections for five years presented with dyspnea, chest tightness, and three-pillow orthopnea. Echocardiogram showed moderate pericardial effusion with early signs of tamponade. Adalimumab was discontinued. He was started on colchicine and steroids for a high suspicion of drug-induced serositis. With the increased use of tumor necrosis factor-alpha antagonists, adverse reactions such as ATIL will become more common. Such cases need to be reported to spread awareness of this possible complication and avoid any delay in treatment and care.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
Cureus
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos